BGDO | Belgian Group of Digestive Oncology

What BGDO | Belgian Group of Digestive Oncology does

BGDO (Belgian Group of Digestive Oncology) is an independent non-profit scientific association founded in 2003 and headquartered in Zaventem, Belgium. It is open to physicians and researchers with an interest in gastrointestinal oncology and operates with a small staff of five and a 12-member board whose composition is governed by strict academic/non-academic, linguistic, and institutional representation rules. The organization's mission is to improve quality of care in GI oncology through multidisciplinary collaboration, teaching, research stimulation, and the development of protocols and guidelines.

BGDO's core product is the DNET (Digestive Neuroendocrine Tumor) Registry, an electronic database operational since 2000 that collects epidemiological and medicinal data on patients with digestive neuroendocrine tumors. Beyond the registry, BGDO sponsors and participates in investigator-driven clinical trials (including PETACC-6, PETACC-8, REACH-IN, MAGNET, QOLINPAC, ASPIRIN, ECHO, LAP07) and has been legally recognized as Sponsor for non-commercial clinical trials in Belgium. Its education portfolio comprises an Annual Scientific Meeting, a multi-day Masterclass held at Domaine de Ronchinne, and recurring webinars summarizing ASCO, ESMO, and ENETS updates. The organization also administers the BGDO Award and BGDO DNET Award (each EUR 2,500) for researchers under 40, and co-authored the cross-societal DPD-deficiency screening recommendation published in Acta Clinica Belgica.

BGDO's revenue model is built on three streams: individual membership fees (EUR 100/year for physicians, EUR 50/year for trainees), event registration fees for meetings, masterclasses, and webinars, and sponsorship funding from approximately 12 pharmaceutical and biotech companies (AstraZeneca, MSD, Roche, Merck, Bristol-Myers Squibb, Servier, Ipsen, Amgen, Pierre Fabre, Takeda, BeOne, Serb Pharmaceuticals). It distributes its content and manages membership through its website (bgdo.org) and in-person events across Belgium, with international collaboration partners including FFCD (France), ESDO (Europe), and LUMC (Netherlands).

Name

BGDO | Belgian Group of Digestive Oncology

Legal name

BGDO - Belgian Group of Digestive Oncology

Website

https://bgdo.org

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

BGDO is a Belgian non-profit scientific association founded in 2003 that brings together physicians and researchers in gastrointestinal oncology through clinical trial sponsorship, the DNET neuroendocrine tumor registry, and a recurring calendar of annual meetings, masterclasses, and webinars.

Ownership category

akta.pro rank

Product category

Medical Professional Association - Gastrointestinal Oncology

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Gastrointestinal Oncology (HLAKAFAK)

Keywords

• Gastrointestinal oncology research
• Clinical trial sponsorship
• Medical professional education
• Digestive oncology association
• Investigator driven trials

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Membership fees: Annual membership fees from physicians and researchers in the field of gastrointestinal oncology. Physician membership costs 100 EUR per year, trainee membership costs 50 EUR per year.
2. Event registration fees: Revenue generated from registration fees for educational events including annual meetings, masterclasses, and webinars. Non-members pay 100 EUR for annual meetings, trainees pay 50 EUR. Masterclass pricing ranges from 80 EUR (trainee member) to 450 EUR (physician non-member).
3. Sponsorship funding: Funding from pharmaceutical and healthcare industry sponsors including AstraZeneca, MSD, Roche, Merck, Bristol-Myers Squibb, Servier, Ipsen, Amgen, Pierre Fabre, Takeda, BeOne, and Serb Pharmaceuticals. Sponsorships support educational meetings, BGDO Awards, and clinical research protocols.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

BGDO is an independent non-profit scientific association that supports physicians and researchers in gastrointestinal oncology across Belgium. Its fundamental offerings include the DNET Registry (an electronic database for digestive neuroendocrine tumor patient data since 2000), sponsorship and coordination of investigator-driven non-commercial clinical trials (e.g., ASPIRIN, REACH-IN, MAGNET, QOLINPAC), and structured educational programs including an annual scientific meeting, an intensive two-day Masterclass, and recurring webinars covering updates from ASCO, ESMO, and ENETS. The organization also funds original GI oncology research through its BGDO Award and BGDO DNET Award (each EUR 2,500) and develops clinical guidelines such as the joint DPD-deficiency screening recommendation published in Acta Clinica Belgica.

Product overview

BGDO (Belgian Group of Digestive Oncology) is an independent non-profit scientific association created in 2003, open to physicians and researchers interested in gastrointestinal oncology. The organization operates a portfolio of services including the DNET Registry (an electronic database for digestive neuroendocrine tumor patient data), clinical trial sponsorship and management, educational programs (annual meetings, masterclasses, webinars), research grants (BGDO Awards and DNET Awards), and clinical guidelines. The DNET Registry serves as the core data collection infrastructure, while clinical trials, educational webinars, and masterclasses form the primary member engagement and knowledge-sharing services.

Differentiator

Problem solved

Functional benefit

Brands

• DNET Registry: Digestive Neuroendocrine Tumor registry collecting epidemiological and medicinal data of patients suffering from digestive neuro-endocrine tumours via an electronic database

Products and services

• DNET Registry Electronic database that collects epidemiological and medicinal data of patients suffering from digestive neuro-endocrine tumours, serving as the core data infrastructure for BGDO's neuroendocrine tumor research program.
• Clinical Trial Sponsorship and Management Sponsorship, coordination, and management of non-commercial investigator-driven clinical trials for gastrointestinal cancers including colorectal, pancreatic, biliary tract, neuroendocrine, and gastric cancer. BGDO is legally recognized as a Sponsor for non-commercial clinical trials in Belgium.
• Educational Webinars Online educational sessions featuring presentations and case discussions on updates from ASCO, ESMO, and ENETS conferences across gastrointestinal oncology topics including esophageal, gastric, colorectal, pancreatic, hepatobiliary, and neuroendocrine cancers.
• BGDO Masterclass Intensive two-day educational course covering advanced topics in digestive oncology including chemotherapy, organ toxicities, new treatment molecules (T-cell engagers, antibody-drug conjugates, RAS-inhibitors, cell and gene therapy), and future cancer care. Held at Domaine de Ronchinne, Maillen, Belgium.
• BGDO Annual Meeting Annual in-person scientific meeting bringing together Belgian experts in gastrointestinal oncology to discuss latest research, clinical updates, and BGDO Award presentations. Free for current-year BGDO members.
• BGDO Awards Program Research grant program awarding EUR 2,500 each through the BGDO Award (for original GI oncology research) and the BGDO DNET Award (for research using DNET Registry data on neuroendocrine tumors). Open to researchers under 40 years old conducting research in Belgium.
• DPD-Deficiency Screening Guidelines Joint Belgian clinical recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine, or tegafur, published in Acta Clinica Belgica and endorsed by BGDO, BSMO, College of Genetics, and BLT.
• BGDO Library Digital repository containing annual meeting slides, newsletters, masterclass presentations, archived clinical trials, and board member documents, with member-restricted access.

Quantifiable outcome

• Joint DPD-deficiency screening recommendation published in ACTA CLINICA BELGICA and endorsed by multiple Belgian medical societies
• +1 more outcomes

Named customers9 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

17 partnerships are on record, tiered core and minor.

• Belgian Society of Medical Oncology (BSMO), College of Genetics (CG), Toxicological Society of Belgium and Luxembourg (BLT)coreStrategic or Co-development Partner · 1 January 2020Collaborative partnership for joint recommendations on screening for DPD-deficiency in patients treated with 5-FU, published in ACTA CLINICA BELGICA. This initiative demonstrates cross-society collaboration in patient safety guidelines.
• Belgian Society of Medical Oncology (BSMO)coreStrategic or Co-development Partner · 1 January 2003BSMO is a key national partner collaborating on initiatives including the joint recommendation on screening for DPD-deficiency, endorsed by both BGDO and BSMO along with the College of Genetics and Toxicological Society of Belgium and Luxembourg.
• FFCD - Fédération Francophone de Cancérologie DigestivecoreStrategic or Co-development PartnerFrench-speaking federation for digestive oncology collaborating on clinical trials and educational initiatives. BGDO participates in collaborative projects including the LAP07 trial with FFCD participation.
• ESDO - European Society of Digestive OncologycoreStrategic or Co-development PartnerEuropean society focused on digestive oncology providing international collaboration opportunities for BGDO members and participation in broader European initiatives.
• AstraZenecaminorOthersPharmaceutical company providing sponsorship funding for BGDO educational activities including the Masterclass and Annual Meeting.
• MSDminorOthersPharmaceutical sponsor supporting BGDO events and educational programs.
• RocheminorOthersPharmaceutical sponsor providing funding for BGDO activities.
• MerckminorOthersPharmaceutical sponsor supporting BGDO Masterclass and educational events.
• Bristol-Myers SquibbminorOthersPharmaceutical sponsor contributing to BGDO educational initiatives.
• ServierminorOthersPharmaceutical company sponsoring BGDO Masterclass and other educational activities.
• IpsenminorOthersPharmaceutical sponsor supporting BGDO educational programs.
• AmgenminorOthersBiotechnology/pharmaceutical sponsor for BGDO activities.
• Pierre FabreminorOthersPharmaceutical sponsor contributing to BGDO events.
• TakedaminorOthersPharmaceutical sponsor supporting BGDO webinars and events.
• BeOneminorOthersPharmaceutical company sponsoring BGDO educational activities.
• Serb PharmaceuticalsminorOthersPharmaceutical sponsor contributing to BGDO activities.
• Leids Universitair Medisch Centrum (LUMC), NetherlandsminorStrategic or Co-development PartnerDutch medical center participating as a coordinating group in the ASPIRIN clinical trial alongside BGDO.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• DCCG - Dutch Colorectal Cancer Group: Dutch national cooperative group for colorectal cancer research. Collaborates with BGDO via LUMC on the ASPIRIN trial and shares BGDO's investigator-initiated trial, registry, and guideline focus on GI cancers.
• EORTC - European Organisation for Research and Treatment of Cancer: Pan-European cooperative group running investigator-initiated cancer trials including in GI cancers. Operates a comparable sponsor model for non-commercial trials and frequently collaborates with national groups like BGDO on trans-European protocols.
• ESDO - European Society of Digestive Oncology: European-level digestive oncology society and named BGDO collaborator. Operates as a continental counterpart to BGDO with overlapping mission (education, trials, guidelines in GI oncology) and shared members across European academic centers.
• FFCD - Fédération Francophone de Cancérologie Digestive: French-speaking cooperative group for digestive oncology. BGDO explicitly collaborates with FFCD on trials such as LAP07 and REACHIN, and both groups share investigator-initiated trial models and multidisciplinary GI oncology focus, making FFCD BGDO's closest functional peer across the language border.
• BSMO - Belgian Society of Medical Oncology: Belgian national society for medical oncology and BGDO's principal national partner. BSMO and BGDO co-endorsed the DPD-deficiency guideline and jointly drive Belgian oncology education and trial activity, with BGDO functioning as the GI-oncology specialist arm of a broader BSMO umbrella.
• ENETS - European Neuroendocrine Tumor Society: European reference society for neuroendocrine tumors, directly overlapping BGDO's DNET Registry mission. ENETS runs an international NET database and centers of excellence program, making it the natural international peer for BGDO's NET-specific activities.

Regional players

• SSO - Swiss Society of Oncology: Swiss national oncology society operating a similar professional society model with clinical guideline, education, and member services. Comparable in scale and function to BGDO but serving Switzerland rather than Belgium.
• DGAV - German Society for Gastroenterology, Digestive and Metabolic Diseases: German national specialty society covering GI oncology and gastroenterology with comparable mission (research, guidelines, education, congress). Functions as a larger geographic peer next door to BGDO with similar cooperative-group dynamics.

Broad incumbents

• ESMO - European Society for Medical Oncology: Largest European professional oncology society covering all tumor types. Serves as the broad incumbent against which national specialty groups like BGDO differentiate; overlaps on guidelines, congresses, and continuing medical education.
• ASCO - American Society of Clinical Oncology: Global incumbent oncology society and a frequent upstream source of the trial data (ASCO-GI) that BGDO translates into Belgian educational content. ASCO sets many of the frameworks BGDO's guidelines reference.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bgdo-belgian-group-of-digestive-oncology

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BGDO | Belgian Group of Digestive Oncology